SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is trending, with community members actively discussing its potential for significant gains and highlighting its availability on platforms like Coinbase. Some users are suggesting it as an alternative investment and pointing to company updates. However, others are questioning its current performance and debating its valuation.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

PJ CRYPTO ($PJ) is trending as community members debate whether it's a buying opportunity or a potential scam. Some investors claim "smart money" is accumulating the token, while others urge caution. The discussion centers on its momentum and potential for future growth within the Solana ecosystem.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed ($RMD) is trending amid speculation of a potential acquisition or partnership with Incannex ($IXHL), fueled by positive Phase 2 data for a sleep apnea treatment and a shared advisory board member. The community is discussing the strategic implications of this collaboration, including ResMed's potential to co-opt a competitor and expand its product offerings beyond CPAP machines. Option traders are actively trading calls, anticipating a significant move pending further developments.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending as investors assess the impact of lowered 2025 revenue guidance amid discussions around the company's discount program. The community is weighing positive news around net income, adjusted EBITDA, and cash position against concerns regarding future dilution and potential revenue shortfalls. Bullish investors remain optimistic about upcoming conference call and potential buyout scenarios.

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences Corp

Edwards Lifesciences is trending as investors assess its potential for a Q3 earnings beat, focusing on TAVR growth and the traction of its valve therapies. Community discussions highlight options activity and analyst ratings, with some noting unusual call volume and target price updates. Some investors are noting that the stock has not moved up as much as hoped after earnings releases.

Xylem, Inc. engages in the design, manufacture, and application of engineered technologies for the water industry. It operates through the following business segments: Water Infrastructure, Applied Water, and Measurement and Control Solutions. The Water Infrastructure segment focuses on the transportation, treatment and testing of water. The Applied Water segment encompasses the uses of water and focuses on the commercial, residential, and industrial end markets. The Measurement and Control Solutions segment focuses on developing technology solutions that enable intelligent use and conservation of critical water and energy resources as well as analytical instrumentation used in the testing of water. The company was founded in 2011 and is headquartered in Washington, DC.

Xylem Inc

XYL is trending due to a potential acquisition of Evoqua, sparking discussions about its implications. While some analysts show confidence with raised price targets and upgrades, there are mixed perspectives, with some downgrades and concerns about the deal's impact. The community is actively evaluating the long-term prospects and valuation of Xylem in light of this development in the water technology sector.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SWFTC is trending as community members discuss its potential, price movement, and possible connection to Chinese markets via a partnership with PCHAIN; some investors are buying the dip and expressing long-term bullish sentiment, while others are wary of pump-and-dump schemes and broader market conditions impacting the token.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community members discuss potential short squeezes and the impact of high error rates. Some traders are drawing comparisons to other stocks, while others express frustration with the sideways trading and question the company's leadership. Discussions also involve the warrants and potential future moves by key figures like Ryan Cohen and Roaring Kitty.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors debate its future amid concerns about credit delinquencies and comparisons to competitors like Upstart and SoFi. Community discussions center on the potential impact of upcoming earnings reports and whether the stock will recover to previous highs. Some traders note institutional buying, while others express skepticism due to past performance and management's communication style.

Rockwell Automation, Inc. engages in the provision of industrial automation and information services. It operates through the following segments: Intelligent Devices, Software and Control, and Lifecycle Services. The Intelligent Devices segment combines a portfolio of smart products that create the foundation of an agile, resilient, and sustainable production system. The Software and Control segment contains a portfolio of production automation and production operations platforms, including hardware and software. The Lifecycle Services segment offers a portfolio of professionally delivered services and value-added solutions. The company was founded by Lynde Bradley and Stanton Allen in 1903 and is headquartered in Milwaukee, WI.

Rockwell Automation Inc

Rockwell Automation ($ROK) is trending amid analyst rating updates, including some raising price targets and one upgrading the stock. Community discussion also highlights the company's potential to benefit from increased automation and reshoring trends, particularly in the industrial sector, as well as the buzz around robotics stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

CytoMed Therapeutics (GDTC) announced on Tuesday that it has submitted a cash bid for an undisclosed sum to the joint administrators of TC BioPharm, effective October 2, for the potential acquisition of its assets.The proposed acquisition will strengthen and deepen CytoMed’s expertise and knowledge in using allogeneic cell therapies for cancer treatment, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166116/0/en/CytoMed-makes-cash-bid-for-potential-acquisition-of-TC-BioPharm-Limited-s-relevant-assets.html">said</a>. The company added that this will help it accelerate its commercialization timeline.TC BioPharm and CytoMed are both clinical-stage biopharmaceutical companies engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment. While TC BioPharm has completed an early-stage clinical trial, CytoMed is currently conducting an early-stage trial in Singapore, evaluating its chimeric antigen receptor (CAR) T cells for a broad range of liquid and solid cancers.The proposed acquisition will be funded by internal resources, the Singapore-based CytoMed said. Shares of the company traded 19% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GDTC">GDTC stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_11_07_48_AM_png_d20bc36299.webp" alt="GDTC's Sentiment Meter and Message Volume as of 11:08 a.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>GDTC's Sentiment Meter and Message Volume as of 11:08 a.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock might be gearing up for a breakout soon.<stembedurl>https://stocktwits.com/Nova_Trades/message/632225590</stembedurl>CytoMed acquired certain assets of Cellsafe International Sdn Bhd, a Malaysian cord blood bank, in October 2024. The acquisition included a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment with more than 12,000 cord blood units, and two freehold real estate properties in which the operation is situated.TC BioPharm is a unit of TC BioPharm Holdings Plc, which was listed on the Nasdaq until March earlier this year. The company said earlier this month that its directors have appointed Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP as joint administrators to its unit to explore options for the sale of the business and assets. The company also said that the parent company continues to operate as usual.GDTC stock is down by 33% this year and up by about 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-enters-130-million-dollar-loan-facility-to-advance-lead-product-candidate-in-treatment-of-lung-cancer/ch6mpu5R3mm">Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did CytoMed Therapeutics Stock Jump 19% Today?

The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 

Equity

The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 


CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ('CytoMed' or 'the Company'), a Singapore biopharmaceutical company that focuses on utilizing its licensed...

CytoMed Launches Shareholder Cell Banking Program

CytoMed Therapeutics Limited (GDTC) has released an update. CytoMed Therapeutics Limited announces a pilot program offering free cell banking to it...

Cytomed Therapeutics to launch complimentary cell banking

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

CytoMed diversifies into regenerative medicineSINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a Singapore-based biopharmaceutical...

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

The Company now has exclusive rights to a Malaysia, US and China patentSINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a...

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

CytoMed Therapeutics Ltd

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$2.29
Prev Close	$2.25
Open	$2.27
Dividend Yield	0.00%
50-Day Moving Average	$1.98
Beta	0.00
Avg. Volume	14,183.67
PE Ratio	-9.53

52-Week High	$4.05
52-Week Low	$1.65
Market Capitalization	$26.87M
EPS (Annual)	-$0.1632
Price to Book	4.71
Revenue Per Employee	$1,209.44
Enterprise Value/EBITDA	N/A

GDTC
CYTOMED THERAPEUTICS LIMITED

Feed

News

Sentiment

Fundamentals

Info

Latest GDTC News

GDTCCYTOMED THERAPEUTICS LIMITED